<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>150</number>
    <updateDate>2023-09-20T14:08:40Z</updateDate>
    <updateDateIncludingText>2023-09-20T14:08:40Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2023-01-30</introducedDate>
    <congress>118</congress>
    <committees>
      <item>
        <systemCode>ssju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2023-03-01T21:18:15Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2023-02-09T14:52:36Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2023-01-30T23:12:11Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2023-03-01</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2023-03-01</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-03-01</actionDate>
        <text>Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-02-09</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on the Judiciary. Ordered to be reported without amendment favorably.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-01-30</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on the Judiciary.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2023-01-30</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>C001056</bioguideId>
        <fullName>Sen. Cornyn, John [R-TX]</fullName>
        <firstName>John</firstName>
        <lastName>Cornyn</lastName>
        <party>R</party>
        <state>TX</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B001277</bioguideId>
        <fullName>Sen. Blumenthal, Richard [D-CT]</fullName>
        <firstName>Richard</firstName>
        <lastName>Blumenthal</lastName>
        <party>D</party>
        <state>CT</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>G000386</bioguideId>
        <fullName>Sen. Grassley, Chuck [R-IA]</fullName>
        <firstName>Chuck</firstName>
        <lastName>Grassley</lastName>
        <party>R</party>
        <state>IA</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>D000563</bioguideId>
        <fullName>Sen. Durbin, Richard J. [D-IL]</fullName>
        <firstName>Richard</firstName>
        <lastName>Durbin</lastName>
        <party>D</party>
        <state>IL</state>
        <middleName>J.</middleName>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001098</bioguideId>
        <fullName>Sen. Cruz, Ted [R-TX]</fullName>
        <firstName>Ted</firstName>
        <lastName>Cruz</lastName>
        <party>R</party>
        <state>TX</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>K000367</bioguideId>
        <fullName>Sen. Klobuchar, Amy [D-MN]</fullName>
        <firstName>Amy</firstName>
        <lastName>Klobuchar</lastName>
        <party>D</party>
        <state>MN</state>
        <sponsorshipDate>2023-01-30</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>B001310</bioguideId>
        <fullName>Sen. Braun, Mike [R-IN]</fullName>
        <firstName>Mike</firstName>
        <lastName>Braun</lastName>
        <party>R</party>
        <state>IN</state>
        <sponsorshipDate>2023-05-02</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>W000800</bioguideId>
        <fullName>Sen. Welch, Peter [D-VT]</fullName>
        <firstName>Peter</firstName>
        <lastName>Welch</lastName>
        <party>D</party>
        <state>VT</state>
        <sponsorshipDate>2023-05-02</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative remedies</name>
        </item>
        <item>
          <name>Civil actions and liability</name>
        </item>
        <item>
          <name>Competition and antitrust</name>
        </item>
        <item>
          <name>Consumer affairs</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Federal Trade Commission (FTC)</name>
        </item>
        <item>
          <name>Health care costs and insurance</name>
        </item>
        <item>
          <name>Inflation and prices</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>Judicial review and appeals</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2023-01-30</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2023-03-24T16:20:19Z</updateDate>
        <text><![CDATA[ <p><strong>Affordable Prescriptions for Patients Act of 2023 </strong></p> <p>This bill prohibits product hopping by drug manufacturers, authorizes the Federal Trade Commission to enforce this prohibition, and imposes limits on patent litigation involving biological products. </p> <p>Generally, <em>product-hopping</em> describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a <em>follow-on product</em> is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantially similar to an indication of the reference drug.</p> <p>The bill presumes product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration (FDA) has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product. </p> <p>A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition.</p> <p>The bill also limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get FDA market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval. </p> </p> <p>]]></text>
      </summary>
      <summary>
        <versionCode>25</versionCode>
        <actionDate>2023-03-01</actionDate>
        <actionDesc>Reported to Senate</actionDesc>
        <updateDate>2023-04-07T15:07:52Z</updateDate>
        <text><![CDATA[ <p><strong>Affordable Prescriptions for Patients Act of 2023 </strong></p> <p>This bill prohibits product hopping by drug manufacturers, authorizes the Federal Trade Commission to enforce this prohibition, and imposes limits on patent litigation involving biological products. </p> <p>Generally, <em>product-hopping</em> describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a <em>follow-on product</em> is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantially similar to an indication of the reference drug.</p> <p>The bill presumes product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration (FDA) has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product. </p> <p>A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition.</p> <p>The bill also limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get FDA market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval. </p> </p> <p>]]></text>
      </summary>
    </summaries>
    <title>Affordable Prescriptions for Patients Act of 2023</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Affordable Prescriptions for Patients Act of 2023</title>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <title>Affordable Prescriptions for Patients Act of 2023</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Affordable Prescriptions for Patients Act of 2023</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Reported to Senate</type>
        <date>2023-03-01T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118s150rs/xml/BILLS-118s150rs.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2023-01-30T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118s150is/xml/BILLS-118s150is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2023-03-01</actionDate>
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
